Why the study?
Are DOACs displacing warfarin as the predominant oral anticoagulant among Medicaid beneficiaries?
Are DOACs displacing warfarin as the predominant oral anticoagulant among Medicaid beneficiaries?
Answers are grounded in this paper and cite their sources.
DOACs are increasingly displacing warfarin as the preferred oral anticoagulant among Medicaid beneficiaries despite higher costs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Caspar et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: